CRC Research Update — November 16, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Monday, November 16, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
RESEARCH
Liver-limited metastatic CRC shows distinct biology with lower KRAS mutation ratesA Netherlands study of 1,026 patients found that 20% had metastases permanently confined to the liver, with lower KRAS mutation frequency and more synchronous presentation compared to other metastatic patterns. (ESMO Gastrointest Oncol)
-
LIVING WITH CRC
Early-onset CRC survival gap tied to later-stage diagnosis, not distinct biologyAnalysis of 80,551 Dutch patients showed that poorer crude survival in under-50 CRC patients was largely explained by more advanced disease at diagnosis; after matching for stage and treatment, survival was similar to 50–69 year-olds. (EClinicalMedicine)
-
TREATMENT
Tucatinib plus trastuzumab shows 38% response in HER2-amplified cancersA phase II trial of 32 patients with HER2 alterations found a 38% response rate in HER2-amplified tumors (including one KRAS co-mutated colon cancer) and 6% in HER2-mutated cancers, with median progression-free survival of 7.4 and 4.0 months, respectively. (NPJ Precis Oncol)
-
TRIAL DATA
Early tumor shrinkage predicts longer survival in metastatic CRC on intensive chemotherapyIn 72 Vietnamese patients treated with first-line mFOLFOXIRI plus bevacizumab, 57% achieved early tumor shrinkage (≥20% reduction at 8 weeks), which was associated with greater depth of response and significantly longer progression-free survival. (Clin Med Insights Oncol)
This week's research highlights the importance of metastatic pattern, stage at diagnosis, and molecular subtype in understanding CRC outcomes and treatment response.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. Readers are added at their own request, by sign-up or through Evolution Labs.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data